pharmaphorum

JULY 5, 2022

The two partners will take an in vivo approach to the problem of so-called sensorineural hearing loss (SNHL) looking at ways to replace sound-detecting hair cells in the inner ear (cochlea) that become damaged in this type of deafness. An estimated 1.57 Astellas is already working on other approaches to treating hearing loss.

In-Vivo 110

In-Vivo Bioinformatics Genetics Licensing 110

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. NASH and type 2 diabetes, as well as for a number of cancers.

In-Vivo 52

In-Vivo Contract Manufacturing Bioinformatics Clinical Development 52

Roots Analysis

JANUARY 27, 2025

Recent protein expression market trends showcase a growing emphasis on cell free protein expression systems, advanced bioinformatics, and the rise of the protein expression market for kits and reagents. Considering their vast potential, close to 50% of the top selling drugs in 2023 were protein therapeutics.

Protein 40

Protein Reagent Marketing Gene 40